Literature DB >> 21969663

Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging--comparison to prior same-center results after MR systems improvements.

David J S Becker-Weidman1, Bobby Kalb, Puneet Sharma, Hiroumi D Kitajima, Christina R Lurie, Zhengjia Chen, James R Spivey, Stuart J Knechtle, Steven I Hanish, N Volkan Adsay, Alton B Farris, Diego R Martin.   

Abstract

PURPOSE: To measure diagnostic performance in the detection of hepatocellular carcinoma (HCC) by using the most recent technology and multiphase gadolinium-enhanced magnetic resonance (MR) imaging and to compare with earlier results at the same institution.
MATERIALS AND METHODS: This retrospective study was institutional review board approved and HIPAA compliant. Informed consent was obtained. Between January 2008 and April 2010, 101 patients underwent liver transplantation and pretransplantation abdominal MR imaging within 90 days. Prospective image interpretations from the clinical record were reviewed for documentation of HCC, including size, number, and location. Liver explant histologic examination provided the reference standard for lesion analysis and was performed in axial gross slices in conjunction with the MR imaging report for direct comparison. Tumors were categorized according to size (≥ 2 cm or <2 cm), and MR imaging detection sensitivity, specificity, predictive values, and accuracy were calculated according to category. The Fisher exact test was used to compare results from this study against prior reported results.
RESULTS: Thirty-five (34.7%) of 101 patients had HCC at explant analysis. Patient-based analysis of all lesions showed a sensitivity and specificity of 97.1% (34 of 35) and 100% (66 of 66), respectively. For lesions 2 cm or larger, MR imaging had a sensitivity and specificity of 100% (23 of 23) and 100% (78 of 78), respectively. For lesions smaller than 2 cm, MR imaging had a sensitivity and specificity of 82.6% (19 of 23) and 100% (78 of 78), respectively. Lesion-based sensitivity for all tumors was 91.4% (53 of 58) in the current study, compared with 77.8% in 2007 (P = .07). For lesions smaller than 2 cm, the sensitivity was 87.5% (28 of 32) in the current study, compared with 55.6% previously (P = .02).
CONCLUSION: MR imaging remains a highly accurate diagnostic method for the preoperative evaluation of HCC, and detection of small (<2 cm) tumors has been significantly improved compared with that of earlier studies. © RSNA, 2011.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21969663     DOI: 10.1148/radiol.11110157

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  16 in total

Review 1.  Magnetic resonance imaging of the cirrhotic liver: An update.

Authors:  Agnes Watanabe; Miguel Ramalho; Mamdoh AlObaidy; Hye Jin Kim; Fernanda G Velloni; Richard C Semelka
Journal:  World J Hepatol       Date:  2015-03-27

2.  [Guideline compliant diagnostics of hepatocellular carcinoma].

Authors:  R R Plentz; B Boozari; N P Malek
Journal:  Radiologe       Date:  2014-07       Impact factor: 0.635

3.  Non-invasive detection and complementary diagnosis of liver metastases via chemokine receptor 4 imaging.

Authors:  Hua Yang; Shanshan Tan; Jingjuan Qiao; Yiting Xu; Zongxiang Gui; Yuguang Meng; Bin Dong; Guangda Peng; Oluwatosin Y Ibhagui; Weiping Qian; Jimmy Lu; Zezhong Li; Guimin Wang; Jinping Lai; Lily Yang; Hans E Grossniklaus; Jenny J Yang
Journal:  Cancer Gene Ther       Date:  2022-02-10       Impact factor: 5.854

Review 4.  MRI of hepatocellular carcinoma: an update of current practices.

Authors:  Hina Arif-Tiwari; Bobby Kalb; Surya Chundru; Puneet Sharma; James Costello; Rainner W Guessner; Diego R Martin
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

Review 5.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Authors:  An Tang; Mustafa R Bashir; Michael T Corwin; Irene Cruite; Christoph F Dietrich; Richard K G Do; Eric C Ehman; Kathryn J Fowler; Hero K Hussain; Reena C Jha; Adib R Karam; Adrija Mamidipalli; Robert M Marks; Donald G Mitchell; Tara A Morgan; Michael A Ohliger; Amol Shah; Kim-Nhien Vu; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-21       Impact factor: 11.105

Review 6.  Focal liver lesions: Practical magnetic resonance imaging approach.

Authors:  António P Matos; Fernanda Velloni; Miguel Ramalho; Mamdoh AlObaidy; Aruna Rajapaksha; Richard C Semelka
Journal:  World J Hepatol       Date:  2015-08-08

Review 7.  Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients.

Authors:  Victoria Chernyak; Kathryn J Fowler; Aya Kamaya; Ania Z Kielar; Khaled M Elsayes; Mustafa R Bashir; Yuko Kono; Richard K Do; Donald G Mitchell; Amit G Singal; An Tang; Claude B Sirlin
Journal:  Radiology       Date:  2018-09-25       Impact factor: 11.105

8.  High-spatial and high-temporal resolution dynamic contrast-enhanced perfusion imaging of the liver with time-resolved three-dimensional radial MRI.

Authors:  Ethan K Brodsky; Eric M Bultman; Kevin M Johnson; Debra E Horng; William R Schelman; Walter F Block; Scott B Reeder
Journal:  Magn Reson Med       Date:  2014-03       Impact factor: 4.668

9.  Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.

Authors:  Sahar Semaan; Naik Vietti Violi; Sara Lewis; Manjil Chatterji; Christopher Song; Cecilia Besa; James S Babb; M Isabel Fiel; Myron Schwartz; Swan Thung; Claude B Sirlin; Bachir Taouli
Journal:  Eur Radiol       Date:  2019-10-31       Impact factor: 5.315

10.  [Diagnosis of and therapy for hepatocellular carcinoma].

Authors:  T F Greten; N P Malek; S Schmidt; J Arends; P Bartenstein; W Bechstein; T Bernatik; M Bitzer; A Chavan; M Dollinger; D Domagk; O Drognitz; M Düx; S Farkas; G Folprecht; P Galle; M Geißler; G Gerken; D Habermehl; T Helmberger; K Herfarth; R T Hoffmann; M Holtmann; P Huppert; T Jakobs; M Keller; J Klempnauer; F Kolligs; J Körber; H Lang; F Lehner; F Lordick; A Lubienski; M P Manns; A Mahnken; M Möhler; C Mönch; P Neuhaus; C Niederau; M Ocker; G Otto; P Pereira; G Pott; J Riemer; K Ringe; U Ritterbusch; E Rummeny; P Schirmacher; H J Schlitt; K Schlottmann; V Schmitz; A Schuler; H Schulze-Bergkamen; D von Schweinitz; D Seehofer; H Sitter; C P Straßburg; C Stroszczynski; D Strobel; A Tannapfel; J Trojan; I van Thiel; A Vogel; F Wacker; H Wedemeyer; H Wege; A Weinmann; C Wittekind; B Wörmann; C J Zech
Journal:  Z Gastroenterol       Date:  2013-11-15       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.